<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To determine whether there is a relationship between 1,5-anhydroglucitol (1,5-AG), a marker of postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and glycaemic variability, and the presence of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and <z:mp ids='MP_0002871'>albuminuria</z:mp> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Five hundred and sixty-seven patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> &lt; 133 μmol/l), who were enrolled in the Seoul Metro-City <z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program (SMC-DPP), were cross-sectionally assessed by multivariate logistic regression analysis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: After controlling for age, sex, binary HbA(1c) levels, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, systolic blood pressure, smoking status, history of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, and the use of <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi>/angiotensin receptor blocker medication, the odds ratios (95% CI) of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> were 2.86 (1.12-7.25) for the first (lowest) quartile of 1,5-anhydroglucitol, 2.87 (1.25-6.61) for the second quartile and 0.88 (0.35-2.22) for the third quartile compared with the fourth quartile (P for trend = 0.010) </plain></SENT>
<SENT sid="3" pm="."><plain>Conversely, the associations between 1,5-anhydroglucitol and clinical <z:mp ids='MP_0002871'>albuminuria</z:mp> were non-significant after adjustment </plain></SENT>
<SENT sid="4" pm="."><plain>Subjects with low 1,5-anhydroglucitol (&lt; 10.0 μg/ml) were more likely to experience diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> than those with high 1,5-anhydroglucitol (≥ 10.0 μg/ml) under moderate <z:chebi fb="105" ids="17234">glucose</z:chebi> control (HbA(1c) &lt; 8%, 64 mmol/mol) and there were no significant differences in the prevalence of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> between the subgroup with HbA(1c) &lt; 8% (64 mmol/mol) and low 1,5-anhydroglucitol and the subgroup with HbA(1c) ≥ 8% (64 mmol/mol) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: 1,5-Anhydroglucitol levels show close associations with diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, especially among patients under moderate <z:chebi fb="105" ids="17234">glucose</z:chebi> control, but not with <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that 1,5-anhydroglucitol might be a complementary marker for targeting higher risk group </plain></SENT>
</text></document>